Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAFF CAR-T · 1 trial · 1 indication
Maximum tolerated dose.
| Arm | Type | Description |
|---|---|---|
| LMY-920 dose escalation | EXPERIMENTAL | Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design. |
| Name | Type | Description |
|---|---|---|
| BAFF CAR-T | DRUG | Autologous CAR-T cell therapy expressing the BAFF-ligand. |
Inclusion Criteria: 1. Subjects must have histologically confirmed non-Hodgkin lymphoma relapsed after 2 or more lines of therapy or disease refractory to chemotherapy (defined as progressive disease or stable disease lasting ≤6 months, as best response to most recent chemotherapy regimen; or disea...
BAFF CAR-T is an investigational cell therapy being studied for the treatment of B-cell non-Hodgkin lymphoma, including lymphoma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
BAFF CAR-T is designed to target BAFF, a protein involved in B-cell survival and proliferation. By engineering a patient's T cells to recognize BAFF, the therapy aims to attack malignant B cells in non-Hodgkin lymphoma.
BAFF CAR-T is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The therapy is currently in Phase 1 clinical trials.
BAFF CAR-T is in Phase 1 clinical development. It is an investigational therapy, meaning it has not yet been approved by regulatory authorities and is still being evaluated for safety and efficacy in clinical trials.
BAFF CAR-T is being studied in a Phase 1 clinical trial with the identifier NCT05312801. This trial is recruiting participants with B-cell non-Hodgkin lymphoma in the United States and aims to enroll approximately 20 patients.
Yes, BAFF CAR-T is also known as LMY-920. The Phase 1 clinical trial for this therapy is titled 'Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma,' confirming that both names refer to the same investigational cell therapy.